Bolt Biotherapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-20.0%projected annual EPS growth
Analyst Coverage
2analysts covering
FY EPS (est.)
-$238.28next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, and Marketable Securities Quarterly23.9MTarget: Sufficient to fund operations into 2027
BDC-4182 Phase 1/2 Trial Enrollment QuarterlyTarget: Complete dose-escalation portion of the study
Watch Items
- BDC-4182 Initial Clinical Data ReleaseTrigger: Initial clinical data presentation in 3Q 2026Action: Evaluate safety, step-up dosing tolerability, and early signs of anti-tumor efficacy to validate the next-generation Boltbody ISAC platform.
- Strategic Partnering for BDC-3042 and Preclinical AssetsTrigger: Securing a development partner or external fundingAction: Resume clinical development of BDC-3042 (Dectin-2 agonist) and preclinical programs (CEA ISAC, PD-L1 ISAC) which are currently on hold.
Research as of 20 Jun 2026